What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide important financial information related to Gilead Sciences' proposed acquisition of Pharmasset, Inc. This includes Pharmasset's audited financial statements and pro forma combined financial statements of the two companies.

What specific financial statements are included for Pharmasset?

The filing includes Pharmasset's audited financial statements as of September 30, 2011 and 2010, and for the years ended September 30, 2011, 2010, and 2009. Reports from Grant Thornton LLP are also included.

What is the significance of the 'Computation of the Ratio of Earnings to Fixed Charges'?

This computation is important for investors as it indicates Gilead's ability to cover its fixed charges (like interest expense) with its earnings. The updated filing provides this ratio for historical periods and the recent interim period up to September 30, 2011, which is relevant in the context of the acquisition and any potential financing it entails.

When did Gilead announce the acquisition of Pharmasset?

While this 8-K filing doesn't explicitly state the announcement date of the acquisition, it was filed on December 6, 2011, in connection with the proposed acquisition, suggesting the announcement or significant progress towards it occurred around this time.

GILD 8-K SEC Disclosure

Summary

This Form 8-K filing by Gilead Sciences, Inc. (GILD) primarily serves to disclose financial information related to its proposed acquisition of Pharmasset, Inc. Investors can find the audited financial statements of Pharmasset as of September 30, 2011 and 2010, and for the fiscal years ended September 30, 2011, 2010, and 2009. Additionally, unaudited pro forma condensed combined financial statements reflecting the potential merger of Gilead and Pharmasset are provided. The filing also includes an updated "Computation of the Ratio of Earnings to Fixed Charges" for Gilead, covering historical periods and a recent interim period, which is important for assessing the company's debt servicing capabilities. These disclosures are crucial for investors evaluating the financial implications and potential synergies of the Pharmasset acquisition.

Key Highlights

1Gilead Sciences is filing Pharmasset's audited financial statements (as of Sept 30, 2011/2010 and for years ended Sept 30, 2011/2010/2009) as part of the proposed acquisition.
2Unaudited pro forma condensed combined financial statements for Gilead and Pharmasset (as of Sept 30, 2011 and for periods ending Sept 30, 2011 and Dec 31, 2010) are being provided.
3The filing includes an updated 'Computation of the Ratio of Earnings to Fixed Charges' for Gilead for historical periods and the nine months ended September 30, 2011.
4The disclosed financial information is directly related to the ongoing acquisition of Pharmasset, Inc.
5These documents are incorporated by reference into the 8-K filing.

GILEAD SCIENCES, INC. 8-K Report, Corporate Update (Dec 6, 2011)

Summary

Key Highlights

Frequently Asked Questions